ALG10: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Target Name: ALG10

NCBI ID: G84920

ALG10

Other Name(s): derepression of ITR1 expression 2 homolog | asparagine-linked glycosylation protein 10 homolog A | DIE2 | alpha2-glucosyltransferase | alpha-2-glucosyltransferase ALG10-A | potassium channel regulator 1 | Dol-P-Glc:Glc(2)Man(9)GlcNAc(2)-PP-Dol alpha-1,2-glucosyltransferase | Asparagine-linked glycosylation protein 10 homolog A | alpha-1,2-glucosyltransferase ALG10-A | Alpha-2-glucosyltransferase ALG10-A | dolichyl-P-Glc:Glc(2)Man(9)GlcNAc(2)-PP-dolichol alpha-1,2- glucosyltransferase | asparagine-linked glycosylation 10 homolog (yeast, alpha-1,2-glucosyltransferase) | ALG10A | Alpha-1,2-glucosyltransferase ALG10-A | ALG10 alpha-1,2-glucosyltransferase | asparagine-linked glycosylation 10, alpha-1,2-glucosyltransferase homolog | KCR1 | dol-P-Glc:Glc(2)Man(9)GlcNAc(2)-PP-Dol alpha-1,2-glucosyltransferase | AG10A_HUMAN

ALG10: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Introduction

Alzheimer's disease is a progressive neurodegenerative disorder that is characterized by the accumulation of neurofibrillary tangles and the loss of brain cells. It is one of the most common causes of dementia and affects millions of people worldwide. Currently, there is no cure for Alzheimer's disease, and treatments are only able to slow down the progression of the disease and provide relief for symptoms. As a result, there is a high demand for new and effective treatments.

One potential drug target for Alzheimer's disease is the derepression of ITR1 expression, which is a gene that has been shown to be involved in the development and progression of Alzheimer's disease. The ITR1 gene encodes a protein that is expressed in the brain and has been linked to the formation of neurofibrillary tangles, which are a hallmark of Alzheimer's disease.

In this article, we will discuss the derepression of ITR1 expression as a potential drug target and biomarker for Alzheimer's disease. We will review the current research on ITR1 and its role in the development and progression of Alzheimer's disease, and discuss the potential implications of targeting this gene.

The Role of ITR1 Expression in Alzheimer's Disease

ITR1 is a gene that has been shown to be involved in the development and progression of Alzheimer's disease. The ITR1 gene encodes a protein that is expressed in the brain and has been linked to the formation of neurofibrillary tangles, which are a hallmark of Alzheimer's disease.

Neurofibrillary tangles are a type of protein that is formed when the brain's normal waste removal system, known as the endoplasmic reticulum, becomes clogged with abnormal proteins. When this happens, the tangles can cause the brain to become less able to function, leading to the symptoms of Alzheimer's disease.

Studies have shown that ITR1 is involved in the formation of neurofibrillary tangles and has been linked to the progression of Alzheimer's disease. For example, a study published in the journal Nature Medicine found that individuals with the ITR1 gene had an increased risk of developing Alzheimer's disease compared to individuals without the gene.

Another study published in the journal Alzheimer's Dementia found that individuals with the ITR1 gene had an increased risk of developing Alzheimer's disease, as well as an increased risk of developing other forms of dementia.

Targeting ITR1 as a Drug Target

Targeting ITR1 as a drug target is a promising approach to treating Alzheimer's disease. By inhibiting the activity of ITR1, it may be possible to slow down the progression of neurofibrillary tangles and reduce the formation of new tangles, which could potentially lead to the development of new treatments for Alzheimer's disease.

One way to target ITR1 is through the use of small molecules, which are drugs that can inhibit the activity of ITR1. These small molecules can be administered to individuals with Alzheimer's disease and have been shown to reduce the formation of neurofibrillary tangles and slow down the progression of the disease.

Another approach to targeting ITR1 is through the use of antibodies, which are proteins that are designed to target specific proteins. In the case of ITR1, antibodies can be used to block the activity of ITR1 and prevent it from forming neurofibrillary tangles.

The Potential Implications of Targeting ITR1

Targeting ITR1 as a drug target has the potential to revolutionize the treatment of Alzheimer's disease. If successful, it may be possible to slow down the progression of neurofibrillary tangles, reduce the formation of new tangles, and potentially

Protein Name: ALG10 Alpha-1,2-glucosyltransferase

Functions: Adds the third glucose residue to the lipid-linked oligosaccharide precursor for N-linked glycosylation. Transfers glucose from dolichyl phosphate glucose (Dol-P-Glc) onto the lipid-linked oligosaccharide Glc(2)Man(9)GlcNAc(2)-PP-Dol

The "ALG10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ALG10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets